Identification of distinct human invariant natural killer T-cell response phenotypes to alpha-galactosylceramide
<p>Abstract</p> <p>Background </p> <p>Human CD1d-restricted, invariant natural killer T cells (iNKT) are a unique class of T lymphocytes that recognise glycolipid antigens such as α-galactosylceramide (αGalCer) and upon T cell receptor (TCR) activation produce both Th1...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2008-12-01
|
| Series: | BMC Immunology |
| Online Access: | http://www.biomedcentral.com/1471-2172/9/71 |
| _version_ | 1818766274521464832 |
|---|---|
| author | Besra Gurdyal S Illarionov Petr A Willcox Carrie R Mura Manuela Curbishley Stuart M Croudace Joanne E Adams David H Lammas David A |
| author_facet | Besra Gurdyal S Illarionov Petr A Willcox Carrie R Mura Manuela Curbishley Stuart M Croudace Joanne E Adams David H Lammas David A |
| author_sort | Besra Gurdyal S |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background </p> <p>Human CD1d-restricted, invariant natural killer T cells (iNKT) are a unique class of T lymphocytes that recognise glycolipid antigens such as α-galactosylceramide (αGalCer) and upon T cell receptor (TCR) activation produce both Th1 and Th2 cytokines. iNKT cells expand when cultured <it>in-vitro </it>with αGalCer and interleukin 2 (IL-2) in a CD1d-restricted manner. However, the expansion ratio of human iNKT cells varies between individuals and this has implications for attempts to manipulate this pathway therapeutically. We have studied a panel of twenty five healthy human donors to assess the variability in their <it>in-vitro </it>iNKT cell expansion responses to stimulation with CD1d ligands and investigated some of the factors that may influence this phenomenon.</p> <p>Results </p> <p>Although all donors had comparable numbers of circulating iNKT cells their growth rates <it>in-vitro </it>over 14 days in response to a range of CD1d ligands and IL-2 were highly donor-dependent. Two reproducible donor response patterns of iNKT expansion were seen which we have called 'strong' or 'poor' iNKT responders. Donor response phenotype did not correlate with age, gender, frequency of circulating iNKT, or with the CD1d ligand utilised. Addition of exogenous recombinant human interleukin 4 (IL-4) to 'poor' responder donor cultures significantly increased their iNKT proliferative capacity, but not to levels equivalent to that of 'strong' responder donors. However in 'strong' responder donors, addition of IL-4 to their cultures did not significantly alter the frequency of iNKT cells in the expanded CD3<sup>+ </sup>population.</p> <p>Conclusion </p> <p>(i) <it>in-vitro </it>expansion of human iNKT cells in response to CD1d ligand activation is highly donor variable, (ii) two reproducible patterns of donor iNKT expansion were observed, which could be classified into 'strong' and 'poor' responder phenotypes, (iii) donor iNKT response phenotypes did not correlate with age, gender, frequency of circulating iNKT cells, or with the CD1d ligand utilised, (iv) addition of IL-4 to 'poor' but not 'strong' responder donor cultures significantly increased their <it>in-vitro </it>iNKT cell expansion to αGalCer.</p> |
| first_indexed | 2024-12-18T08:31:23Z |
| format | Article |
| id | doaj.art-98949c4090374f7a9449fab8736e6fb2 |
| institution | Directory Open Access Journal |
| issn | 1471-2172 |
| language | English |
| last_indexed | 2024-12-18T08:31:23Z |
| publishDate | 2008-12-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Immunology |
| spelling | doaj.art-98949c4090374f7a9449fab8736e6fb22022-12-21T21:14:27ZengBMCBMC Immunology1471-21722008-12-01917110.1186/1471-2172-9-71Identification of distinct human invariant natural killer T-cell response phenotypes to alpha-galactosylceramideBesra Gurdyal SIllarionov Petr AWillcox Carrie RMura ManuelaCurbishley Stuart MCroudace Joanne EAdams David HLammas David A<p>Abstract</p> <p>Background </p> <p>Human CD1d-restricted, invariant natural killer T cells (iNKT) are a unique class of T lymphocytes that recognise glycolipid antigens such as α-galactosylceramide (αGalCer) and upon T cell receptor (TCR) activation produce both Th1 and Th2 cytokines. iNKT cells expand when cultured <it>in-vitro </it>with αGalCer and interleukin 2 (IL-2) in a CD1d-restricted manner. However, the expansion ratio of human iNKT cells varies between individuals and this has implications for attempts to manipulate this pathway therapeutically. We have studied a panel of twenty five healthy human donors to assess the variability in their <it>in-vitro </it>iNKT cell expansion responses to stimulation with CD1d ligands and investigated some of the factors that may influence this phenomenon.</p> <p>Results </p> <p>Although all donors had comparable numbers of circulating iNKT cells their growth rates <it>in-vitro </it>over 14 days in response to a range of CD1d ligands and IL-2 were highly donor-dependent. Two reproducible donor response patterns of iNKT expansion were seen which we have called 'strong' or 'poor' iNKT responders. Donor response phenotype did not correlate with age, gender, frequency of circulating iNKT, or with the CD1d ligand utilised. Addition of exogenous recombinant human interleukin 4 (IL-4) to 'poor' responder donor cultures significantly increased their iNKT proliferative capacity, but not to levels equivalent to that of 'strong' responder donors. However in 'strong' responder donors, addition of IL-4 to their cultures did not significantly alter the frequency of iNKT cells in the expanded CD3<sup>+ </sup>population.</p> <p>Conclusion </p> <p>(i) <it>in-vitro </it>expansion of human iNKT cells in response to CD1d ligand activation is highly donor variable, (ii) two reproducible patterns of donor iNKT expansion were observed, which could be classified into 'strong' and 'poor' responder phenotypes, (iii) donor iNKT response phenotypes did not correlate with age, gender, frequency of circulating iNKT cells, or with the CD1d ligand utilised, (iv) addition of IL-4 to 'poor' but not 'strong' responder donor cultures significantly increased their <it>in-vitro </it>iNKT cell expansion to αGalCer.</p>http://www.biomedcentral.com/1471-2172/9/71 |
| spellingShingle | Besra Gurdyal S Illarionov Petr A Willcox Carrie R Mura Manuela Curbishley Stuart M Croudace Joanne E Adams David H Lammas David A Identification of distinct human invariant natural killer T-cell response phenotypes to alpha-galactosylceramide BMC Immunology |
| title | Identification of distinct human invariant natural killer T-cell response phenotypes to alpha-galactosylceramide |
| title_full | Identification of distinct human invariant natural killer T-cell response phenotypes to alpha-galactosylceramide |
| title_fullStr | Identification of distinct human invariant natural killer T-cell response phenotypes to alpha-galactosylceramide |
| title_full_unstemmed | Identification of distinct human invariant natural killer T-cell response phenotypes to alpha-galactosylceramide |
| title_short | Identification of distinct human invariant natural killer T-cell response phenotypes to alpha-galactosylceramide |
| title_sort | identification of distinct human invariant natural killer t cell response phenotypes to alpha galactosylceramide |
| url | http://www.biomedcentral.com/1471-2172/9/71 |
| work_keys_str_mv | AT besragurdyals identificationofdistincthumaninvariantnaturalkillertcellresponsephenotypestoalphagalactosylceramide AT illarionovpetra identificationofdistincthumaninvariantnaturalkillertcellresponsephenotypestoalphagalactosylceramide AT willcoxcarrier identificationofdistincthumaninvariantnaturalkillertcellresponsephenotypestoalphagalactosylceramide AT muramanuela identificationofdistincthumaninvariantnaturalkillertcellresponsephenotypestoalphagalactosylceramide AT curbishleystuartm identificationofdistincthumaninvariantnaturalkillertcellresponsephenotypestoalphagalactosylceramide AT croudacejoannee identificationofdistincthumaninvariantnaturalkillertcellresponsephenotypestoalphagalactosylceramide AT adamsdavidh identificationofdistincthumaninvariantnaturalkillertcellresponsephenotypestoalphagalactosylceramide AT lammasdavida identificationofdistincthumaninvariantnaturalkillertcellresponsephenotypestoalphagalactosylceramide |